Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.


Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?


Please Try Again {{ error }}

Send my password

An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Global Legal Cannabis Market Projected to Increase in Value

V.SPN, ISOLF, FFRMF, CVSI News Commentary

PR Newswire

NEW YORK, March 27, 2018 /PRNewswire/ --

According to a report by Ameri Research Inc., the global legal cannabis market was valued at $14.3 billion in 2016 and is estimated to grow at a CAGR of 21.1% between 2017 to 2024, while reaching a value of $63.5 billion by 2024. The market is going through a period of robust growth because of increasing legalization and decriminalization of cannabis products across North America. The report specifies that the legalization trend is moving beyond the U.S. region. Data by Arcview Market Research clarifies that growth of the legal cannabis industry will reaccelerate beginning 2018, as adult use sales ramp up in Canada, California, and Massachusetts along with medical sales in Florida. Snipp Interactive Inc. (OTC: SNIPF), PotNetwork Holding, Inc. (OTC: POTN), Isodiol International Inc. (OTC: ISOLF), Future Farm Technologies Inc. (OTC: FFRMF), CV Sciences, Inc. (OTC: CVSI)

The report also noted that Europe will have the potential to become one of the largest medical cannabis markets in the world. Tom Adams, Editor-in-Chief at Arcview Market Research and Principal Analyst at BDS Analytics, said: "California gets the media attention and Canada gets the investment dollars as they allow adult use, but Germany's move to make cannabis flower available for medical use in pharmacies was really the big news of 2017 from a worldwide perspective…The tables have turned in favor of legalization across the world and we predict that the trend will spread as research continues to support cannabis' effectiveness as a medication."

Snipp Interactive Inc. (OTCQB: SNIPF) is also listed on the TSX Venture Exchange under the ticker (TSX-V: SPN). Yesterday the company, "shared their perspective with The Wise Marketer ( on industry regulations and their impact on marketing in the Cannabis sector along with the use of technology for marketing in this industry.

The Wise Marketer bills itself as the only objective voice serving the $200 billion global loyalty industry. It has 20,000 plus web visitors per month who are high-level marketing executives, senior directors and managers with day-to- day accountability for customer strategy and loyalty. It has more than 15 years of experience covering, commenting on, and educating loyalty practitioners with more than 11,000 active, engaged email subscribers from 50 countries around the world. It launched the Loyalty Academy in 2015 and is the only forum dedicated to educating loyalty professionals in existence. It also publishes The Loyalty Guide - one of the most respected digests for loyalty best-practices and case studies and holds the Loyalty Academy Conference each year, as the only live forum dedicated to exchanging high quality thought among loyalty practitioners.

The article titled "More than Buzz to Cannabis Marketing Resource" touches on the complications arising from an evolving regulatory framework and on the need to leverage experiences that companies like Snipp have had in the alcohol and pharma space to effectively use technology to meet marketing objectives given the challenges of staying compliant across jurisdictions with different regulations. Read the article here:

"The Wise Marketer is one of the most respected and followed resources for loyalty professionals worldwide. The fact that they are interested in covering what companies like Snipp are now doing to drive customer retention in the cannabis industry, points to the fact that the Cannabis industry has come of age and ready to contribute to the overall knowledge base for marketers," commented Atul Sabharwal, CEO and Founder of Snipp. "Our proven technology solutions in regulated industries will help transform the way cannabis marketers connect with their consumers as well as with their supply chain. With our recently launched Cannabis Marketing Resource Center and hope to not only contribute to this discussion but also become a focal point for industry discussions and coordination to influence regulation for responsible marketing."

PotNetwork Holding, Inc. (OTC: POTN) is a publicly traded company that acts as a holding company for its subsidiaries, First Capital Venture Co., the owner of Diamond CBD, Inc., the maker of Diamond CBD oils, PotNetwork, Inc., and Blockchain Crypto Technology Corp. Recently, the company announced that the company's wholly owned subsidiary, Diamond CBD Inc., will exhibit its innovative animal health and wellness products at the Global Pet Expo held in Orlando, Florida. Diamond CBD Inc.'s Medipets product line is a first of its kind, 100% natural and organic cannabinoid oil-based health and wellness solution for dogs and cats. Along with the company's Pet CBD Food for small, medium, large dogs and cats, these products offer pet owners a new way to support their animal's mood in a non-invasive, non-toxic way. PotNetwork Holding, Inc. has seen consistent growth in the marketing and distribution of its brands including Diamond CBD Inc.

Isodiol International Inc. (OTCQB: ISOLF) is the market leader in pharmaceutical grade phytochemical compounds and the industry leader in the manufacturing and development of CBD consumer products. Isodiol is the pioneer of many firsts for the cannabis industry including commercialization of 99%+ pure, bioactive pharmaceutical grade cannabinoids, micro-encapsulations, and nanotechnology for the highest quality consumable and topical skin care products. Recently, the company announced that its wholly owned subsidiary, IsoBev Inc., has reached a definitive agreement to acquire 100% of Azure Bottling LLC, a premier water bottling facility located in Leesburg, Florida. Azure has in place the manufacturing and distribution agreements to supply water to Sysco, McArthur Dairy / Dean Foods, and Dollar General Stores throughout the United States.  In total, Azure full capacity runs approximately 5.3 million bottles per month and expects this to increase to approximately 8.58 million bottles after space and efficiency improvements over the next several months.

Future Farm Technologies Inc. (OTCQX: FFRMF) is a Canadian company with projects throughout North America including California, Florida and Maryland. The Company's business model includes developing and acquiring technologies that will position it as a leader in the evolution of Controlled Environment Agriculture (CEA) for the global production of various types of plants, with a focus on cannabis. Recently, the company announced that it has signed a Letter of Intent to acquire a 50% interest in and to enter into a definitive joint venture agreement with CEPG Consulting and Design Inc. of St John's, Newfoundland. The joint venture is formed to begin operations for a cannabis and hemp breeding program under its previously announced joint venture with Rahan Meristem Ltd., a world renown global agro-biotechnology company incorporated in the State of Israel. The joint venture will operate out of both an existing building and 6,000 square feet of newly constructed laboratories.

CV Sciences, Inc. (OTCQB: CVSI) operates two distinct business segments: a drug development division focused on developing and commercializing novel therapeutics utilizing synthetic CBD; and, a consumer product division focused on manufacturing, marketing and selling plant-based CBD products to a range of market sectors. CV Sciences' Pharmaceutical Division is developing synthetically‐formulated cannabidiol‐based medicine, pursuing the approval of the U.S. Food and Drug Administration (FDA) for drugs with specific indications utilizing cannabidiol as the active pharmaceutical ingredient. CV Sciences has achieved promising preclinical results in the development of cannabinoid medicines for treatment of a range of medical conditions. In 2017, the company announced it has been named on Deloitte's Technology Fast 500™, an annual ranking of the fastest growing companies in the technology, media, telecommunications, life sciences and energy tech sectors in North America. The Deloitte Technology Fast 500 is based on percentage of revenue growth from fiscal year 2013 to 2016, with CV Sciences growing by 403% during this period.

Subscribe Now! Watch us report LIVE

Follow us on Twitter for real time Financial News Updates:

Follow and talk to us on Instagram:

Facebook Like Us to receive live feeds:

About, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, creates 100% unique original content. also provides financial news PR dissemination, branding, marketing and advertising for third parties for corporate news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.

Please Note: is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on (the 'Site') is either original financial news or paid advertisements provided [exclusively] by our affiliates (sponsored content),, a financial news media and marketing firm enters into media buys or service agreements with the companies which are the subject to the articles posted on the Site or other editorials for advertising such companies. We are not an independent news media provider and therefore do not represent or warrant that the information posted on the Site is accurate, unbiased or complete. receives fees for producing and presenting high quality and sophisticated content on along with other financial news PR media services. does not offer any personal opinions, recommendations or bias commentary as we purely incorporate public market information along with financial and corporate news. only aggregates or regurgitates financial or corporate news through our unique financial newswire and media platform. For snipp interactive inc., financial news dissemination and PR services, has been compensated five thousand dollars by the company. Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this editorial or site, or a combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion of the engagement. will always disclose any compensation in securities or cash payments for financial news PR advertising. does not undertake to update any of the information on the editorial or Site or continue to post information about any companies the information contained herein is not intended to be used as the basis for investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy, hold or sell any security., members and affiliates are not responsible for any gains or losses that result from the opinions expressed on this editorial or Site, company profiles, quotations or in other materials or presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance, and financial condition. By accessing this editorial and website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor. This publication is provided by Each investor is solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use, please visit:

Media Co ntact: